Apraglutide, a novel once‐weekly glucagon‐like peptide‐2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open‐label phase 1 and 2 metabolic balance trial

BACKGROUND: Apraglutide is a novel long‐acting glucagon‐like peptide‐2 (GLP‐2) analog designed for once‐weekly subcutaneous dosing, with the potential to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome (SBS) with intestinal insufficiency (SBS...

Descripción completa

Detalles Bibliográficos
Autores principales: Eliasson, Johanna, Hvistendahl, Mark K., Freund, Nanna, Bolognani, Federico, Meyer, Christian, Jeppesen, Palle B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545924/
https://www.ncbi.nlm.nih.gov/pubmed/35233802
http://dx.doi.org/10.1002/jpen.2362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545924/
https://www.ncbi.nlm.nih.gov/pubmed/35233802
http://dx.doi.org/10.1002/jpen.2362

Ejemplares similares